Anger as NHS deem prostate cancer drug Cabazitaxel 'too expensive'

 

A life-extending drug hailed as a breakthrough for prostate cancer sufferers is too expensive to be used on the NHS, watchdogs ruled today.

Cabazitaxel, which is marketed as Jevtana, can extends the life of late-stage patients by an average of three months.

The National Institute for Health and Clinical Excellence (Nice), which decides which drugs should be offered on the NHS, today confirmed its original decision in January, rejecting an appeal by the drug's manufacturers Sanofi.

But cancer charities said the decision could mean a postcode lottery and effectively prevent thousands of men from accessing life-extending treatment.

Each year around 37,000 men in the UK are diagnosed with prostate cancer and 10,000 die from the disease.

It is the second most common cause of cancer death in men, accounting for 13%.

Nice said that while the drug is clinically effective, at £22,000 per patient it does not offer value for money for the NHS, and there are concerns over side-effects.

Nice chief executive Sir Andrew Dillon said: "We need to be sure that new treatments provide sufficient benefits to patients to justify the significant resources the NHS would need to make available.

"Although cabazitaxel can extend life for some patients, its price remains well above what the independent committee appraising this drug considered acceptable, given the benefits it offers.

"Cabazitaxel is also associated with a number of side effects, and the committee was concerned about the nature of the health-related quality of life information provided by the manufacturer."

Whenever a new drug is made available, the money to fund it has to come from elsewhere in the NHS.

Nice said it must look at the benefit for patients the NHS can get for the money the drug company is asking.

But Professor Jonathan Waxman of Imperial College London said the cost argument was false.

"This decision seeks to limit what we as clinicians can do for our patients and their families," he said.

"The cost argument on which Nice bases their decision is false, giving a much higher estimate of true cost than applies in reality.

"As a result, yet another successful and effective cancer treatment is denied our patients, a mortifying blow to cancer care in England.

"As the only route to access is now the Cancer Drugs Fund, a temporary arrangement that operates very differently around the country, I fear we're heading towards a re-emergence of the postcode lottery."

Emma Malcolm, chief executive of the charity Prostate Action, said: "Cabazitaxel is one of only two licensed drugs available in the UK that offers the hope of precious extra time and quality of life benefits to men living with advanced prostate cancer.

"Nice's decision not to recommend this drug means that men in England with advanced prostate cancer have to access it through the Cancer Drugs Fund.

"We know that there are inconsistencies across the country with how this fund is awarded, which means some men will only be able to access one of these drugs in some areas.

"Men with advanced prostate cancer have so few treatment options available to them that they should be able to access both of these new treatments."

The Cancer Drugs Fund, set up in 2010 to allow access to drugs rejected by Nice or not yet licensed, is only available until 2014 and only applies in England.

Prostate cancer patients are also waiting for Nice to issue their decision on abiraterone, another life-extending treatment, which is due soon.

PA

Life and Style
ebookNow available in paperback
ebooks
ebookA delicious collection of 50 meaty main courses
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Office / Sales Manager

    £22000 - £32000 per annum: Recruitment Genius: Established and expanding South...

    Recruitment Genius: Administrative Assistant / Order Fulfilment

    £14000 per annum: Recruitment Genius: An exciting opportunity to join a thrivi...

    SThree: Trainee Recruitment Consultant

    £18000 - £23000 per annum + Uncapped OTE: SThree: Trainee Recruitment Consulta...

    SThree: Trainee Recruitment Consultant

    £18000 - £23000 per annum + Uncapped OTE: SThree: Trainee Recruitment Consulta...

    Day In a Page

    Refugee crisis: David Cameron lowered the flag for the dead king of Saudi Arabia - will he do the same honour for little Aylan Kurdi?

    Cameron lowered the flag for the dead king of Saudi Arabia...

    But will he do the same honour for little Aylan Kurdi, asks Robert Fisk
    Our leaders lack courage in this refugee crisis. We are shamed by our European neighbours

    Our leaders lack courage in this refugee crisis. We are shamed by our European neighbours

    Humanity must be at the heart of politics, says Jeremy Corbyn
    Joe Biden's 'tease tour': Could the US Vice-President be testing the water for a presidential run?

    Joe Biden's 'tease tour'

    Could the US Vice-President be testing the water for a presidential run?
    Britain's 24-hour culture: With the 'leisured society' a distant dream we're working longer and less regular hours than ever

    Britain's 24-hour culture

    With the 'leisured society' a distant dream we're working longer and less regular hours than ever
    Diplomacy board game: Treachery is the way to win - which makes it just like the real thing

    The addictive nature of Diplomacy

    Bullying, betrayal, aggression – it may be just a board game, but the family that plays Diplomacy may never look at each other in the same way again
    Lady Chatterley's Lover: Racy underwear for fans of DH Lawrence's equally racy tome

    Fashion: Ooh, Lady Chatterley!

    Take inspiration from DH Lawrence's racy tome with equally racy underwear
    8 best children's clocks

    Tick-tock: 8 best children's clocks

    Whether you’re teaching them to tell the time or putting the finishing touches to a nursery, there’s a ticker for that
    Charlie Austin: Queens Park Rangers striker says ‘If the move is not right, I’m not going’

    Charlie Austin: ‘If the move is not right, I’m not going’

    After hitting 18 goals in the Premier League last season, the QPR striker was the great non-deal of transfer deadline day. But he says he'd preferred another shot at promotion
    Isis profits from destruction of antiquities by selling relics to dealers - and then blowing up the buildings they come from to conceal the evidence of looting

    How Isis profits from destruction of antiquities

    Robert Fisk on the terrorist group's manipulation of the market to increase the price of artefacts
    Labour leadership: Andy Burnham urges Jeremy Corbyn voters to think again in last-minute plea

    'If we lose touch we’ll end up with two decades of the Tories'

    In an exclusive interview, Andy Burnham urges Jeremy Corbyn voters to think again in last-minute plea
    Tunisia fears its Arab Spring could be reversed as the new regime becomes as intolerant of dissent as its predecessor

    The Arab Spring reversed

    Tunisian protesters fear that a new law will whitewash corrupt businessmen and officials, but they are finding that the new regime is becoming as intolerant of dissent as its predecessor
    King Arthur: Legendary figure was real and lived most of his life in Strathclyde, academic claims

    Academic claims King Arthur was real - and reveals where he lived

    Dr Andrew Breeze says the legendary figure did exist – but was a general, not a king
    Who is Oliver Bonas and how has he captured middle-class hearts?

    Who is Oliver Bonas?

    It's the first high-street store to pay its staff the living wage, and it saw out the recession in style
    Earth has 'lost more than half its trees' since humans first started cutting them down

    Axe-wielding Man fells half the world’s trees – leaving us just 422 each

    However, the number of trees may be eight times higher than previously thought
    60 years of Scalextric: Model cars are now stuffed with as much tech as real ones

    60 years of Scalextric

    Model cars are now stuffed with as much tech as real ones